Prof. Dr. Julio Vera González

Laboratory of Systems Tumor Immunology / Department of Dermatology

I am a physicist working in systems and precision medicine applied to cancer and autoimmune diseases. I lead an interdisciplinary team that combines computational modeling, bioinformatics, multi-criteria decision algorithms, and network biology to cancer diagnostics and therapy.

Research projects

  • Molecular data-driven engineering of immunotherapy
  • Omics, network and machine learning-based classification of skin and prostate cancer patients
  • Multi-layered data-based drug repurposing in therapy-resistant cancer patients

  • TRAIN: Towards Rationalizing Neurodevelopment

    (FAU Funds)

    Term: 1. January 2024 - 31. December 2025
  • ProDia - Protease Aktivität in Plasma-Vesikeln für die prädiktive Diagnostik von Tumorerkrankungen

    (Third Party Funds Single)

    Term: 1. November 2023 - 30. April 2026
    Funding source: Bayerisches Staatsministerium für Wirtschaft, Landesentwicklung und Energie (StMWi) (seit 2018)
  • E034: How neural stem cells shape their regulatory environment in the adult CNS

    (FAU Funds)

    Term: 1. July 2023 - 31. March 2026
    Funding source: Mittelgeber / Förderprogramme
    An adverse local environment ("niche") impairs the activity of neural stem cells (NSCs) in the adult brain. We investigate the new hypothesis that NSCs play an active role in generating favorable and adverse niche conditions. Specifically, we will investigate how dysfunctional NSCs generate adverse niche conditions focusing i) on the composition and the biomechanical properties of the extracellular matrix and ii) on NSC-derived exosomes and their composition.
  • E033: Deubiquitinase Otud7b in oligodendrocyte differentiation and CNS myelination

    (FAU Funds)

    Term: 1. July 2023 - 31. December 2025
    Specific regulation of protein degradation by the ubiquitin-proteasome system plays important roles in myelination, remyelination and neurodegenerative diseases. I want to analyse the functions of the deubiquitinase Otud7b in oligodendrocytes in vitro and in vivo in an oligodendrocyte-specific Otud7b knockout mouse model and identify functional targets of Otud7b in oligodendrocytes to deepen the understanding of posttranscriptional regulatory events during OL differentiation and CNS myelination.
  • M5-IZFK-D043: Mechanisms controlling functionality and persistence of CD19.CAR T-cells

    (FAU Funds)

    Term: 16. March 2023 - 15. September 2025
    CD19-directed chimeric antigen receptor (CAR) T-cells have shown high efficacy in the treatment of B-cell malignancies and are now emerging as a standard approach for patients with relapsed and refractory disease. Despite this progress, a significant portion of patients still experience resistance to treatment. We aim to understand the intrinsic mechanisms controlling persistence and effector functions of CAR T-cells and therefore identify strategies to overcome treatment failure.
  • E037: CtBP1 in oligodendroglial development and myelination

    (FAU Funds)

    Term: 1. February 2023 - 30. November 2025
    Mutations in transcriptional corepressor CtBP1 cause the neurodevelopmental disorder HADDTS. Functional CtBP1 studies in the central nervous system so far focused on neurons. We recently found that CtBP1 is also important in oligodendrocytes. Here we will characterize the oligodendroglial functions of CtBP1 and the underlying cellular and molecular mechanisms in mice and a human ES cell-derived cellular disease model to show that defects in oligodendrogenesis and myelination contribute to HADDTS

2024

2023

2022

2021

2020

Related Research Fields

Contact: